9.71

0.61% -0.06

After Hours: 9.51 -0.20 -2.06%

Ocular Therapeutix Inc (OCUL)

Overview News Price History Option Chain Financials Why OCUL Down? Discussions Forecast

Ocular Therapeutix Inc stock is traded at $9.71, with a volume of 4.14M. It is down -0.61% in the last 24 hours and up +14.37% over the past month. Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Previous Close:

$9.77

Open:

$9.34

24h Volume:

4.14M

Relative Volume:

0.76

Market Cap:

$2.13B

Revenue:

$51.95M

Net Income/Loss:

$-265.94M

P/E Ratio:

-6.7506

EPS:

-1.4384

Net Cash Flow:

$-216.89M

1W Performance:

+4.18%

1M Performance:

+14.37%

6M Performance:

-10.18%

1Y Performance:

+25.61%

1-Day Range:

$9.08

$9.85

1-Week Range:

$9.06

$9.85

52-Week Range:

$6.2301

$16.44

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name

Ocular Therapeutix Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

781-357-4000

Address

15 CROSBY DRIVE, BEDFORD, MA

Employee

325

Twitter

@OCUTX

Next Earnings Date

2026-05-05

Latest SEC Filings

OCUL's Discussions on Twitter

Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCUL Ocular Therapeutix Inc	9.71	2.14B	51.95M	-265.94M	-216.89M	-1.4384
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-15-25	Initiated	Chardan Capital Markets	Buy
Apr-08-25	Initiated	William Blair	Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform
Mar-11-25	Initiated	Needham	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy
May-31-24	Resumed	Piper Sandler	Overweight
Feb-09-24	Initiated	BofA Securities	Buy
Apr-21-23	Initiated	Robert W. Baird	Outperform
Aug-10-22	Resumed	Berenberg	Buy
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy
Nov-13-20	Reiterated	Raymond James	Strong Buy
Aug-10-20	Reiterated	H.C. Wainwright	Buy
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Downgrade	Cowen	Outperform → Market Perform
May-21-19	Reiterated	H.C. Wainwright	Buy
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-18	Initiated	Raymond James	Strong Buy
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy
Jul-26-17	Initiated	H.C. Wainwright	Buy
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	RBC Capital Mkts	Outperform
Aug-11-16	Initiated	JMP Securities	Mkt Outperform
Feb-17-16	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-23-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-13-15	Initiated	Morgan Stanley	Overweight

View All

Ocular Therapeutix Inc Stock (OCUL) Latest News

04:37 AM

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

09:15 AM

09:02 AM

Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss By Investing.com - Investing.com Canada

09:02 AM

Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss - Investing.com

09:02 AM

08:29 AM

Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips - ChartMill

08:29 AM

07:55 AM

OCULAR THERAPEUTIX ($OCUL) Releases Q1 2026 Earnings - Quiver Quantitative

07:55 AM

07:45 AM

Earnings Flash (OCUL) Ocular Therapeutix Posts Q1 Loss $0.40 a Share, vs. FactSet Est of $0.31 Loss - marketscreener.com

07:45 AM

07:37 AM

Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings - TradingView

07:37 AM

07:32 AM

Ocular Therapeutix: Q1 Earnings Snapshot - marketscreener.com

07:32 AM

07:31 AM

Ocular Therapeutix 1Q 2026: Revenue $10.79M, Net income ($88.61M), EPS ($0.4) — 10-Q Summary - TradingView

07:31 AM

07:28 AM

[10-Q] OCULAR THERAPEUTIX, INC Quarterly Earnings Report - Stock Titan

07:28 AM

07:13 AM

Ocular Therapeutix reports Q1 2026: $10.8M revenue, $88.6M net loss, $666.7M cash - TradingView

07:13 AM

07:11 AM

OCUL: AXPAXLI's Phase 3 success in wet AMD drives NDA plans amid rising R&D costs and strong cash position - TradingView

07:11 AM

07:06 AM

Ocular Therapeutix (NASDAQ: OCUL) widens Q1 loss while advancing AXPAXLI Phase 3 trials - Stock Titan

07:06 AM

May 04, 2026

MSN Money - MSN

May 04, 2026

Ocular Therapeutix Q1 2026 earnings preview - MSN

May 04, 2026

Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance UK

May 04, 2026

Ocular Therapeutix earnings up next as AXPAXLI NDA looms By Investing.com - Investing.com South Africa

May 04, 2026

Ocular Therapeutix earnings up next as AXPAXLI NDA looms - Investing.com

May 04, 2026

May 01, 2026